Last edition
News about "Doxorubicin monotherapy "
Sun Pharmaceutical’s partner Philogen, a Swiss-Italian biotechnology company, has provided an update on the Phase III FIBROSARC trial evaluating Fibromun (L19TNF) in combination with doxorubicin versus doxorubicin alone as first-line treatment for patients with advanced or metastatic Soft Tissue Sarcoma (STS).
Doxorubicin Monotherapy | 12/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members